Smart Inhalers Market Size By Product (Dry Powder Inhaler (DPI)- based smart inhalers, Metered Dose Inhaler (MDI)- based smart inhalers), By Disease indication (Chronic Obstructive Pulmonary Disease (COPD), Asthma), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, e-commerce), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 – 2025

Published Date: Sep 2019  |  Report ID: GMI3994  |  Authors: Sumant Ugalmugale

Report Format: PDF   |   Pages: 190   |   Base Year: 2018




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Smart Inhalers Market size was valued at USD  125.9 million in 2018 and is expected to witness 11.3% CAGR from 2019 to 2025.
 

U.S. Smart inhalers Market, By Product Type, 2018 & 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

The smart inhaler market is primarily driven by innovation, where the emphasis is majorly on digital partnerships between pharma and software companies to offer smart inhaler devices due to an alarming increasing prevalence of respiratory disorders. A smart inhaler is considered to be a part of the new-age digital technology, which is designed to improve respiratory disease management. The increasing prevalence of respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) majorly contributes to the growth of smart inhalers market revenue. The continuously growing prevalence of such chronic diseases has led to an upsurge in the demand for efficient respiratory care in recent years.
 

However, the dearth of awareness about the symptoms of COPD and asthma has resulted in most of the people suffering from respiratory diseases remaining undiagnosed and, thus, untreated. This is considered primary factor for hampering the growth of the market. Most of the people suffering from symptoms of COPD are unaware of disease. Still, the use of smart inhalers is not widely supported within the public health system. This is due to the limited availability of reimbursement and low awareness among the patients regarding novel technology. Moreover, the limited availability of the product in emerging regions creates an obstacle, that directly affect the overall smart inhalers industry growth as per the current scenario.
 

Smart Inhalers Market Report Coverage
Report Coverage Details
Base Year: 2018 Market Size in 2018: 125.9 Million (USD)
Historical Data for: 2014 to 2018 Forecast Period: 2019 to 2025
Forecast Period 2019 to 2025 CAGR: 11.3% 2025 Value Projection: 260 Million (USD)
Pages: 190 Tables, Charts & Figures: 177
Geographies covered (16): U.S., Canada, Germany, UK, France, Spain, Italy, Japan, China, India, Australia, Brazil, Mexico, South Africa, Turkey, Saudi Arabia
Segments covered: Product, Disease indication, Distribution channel and Region
Companies covered (10): AstraZeneca plc, GlaxoSmithKline, Aptar Pharma, Novartis AG, Boehringer Ingelheim, Teva Pharmaceuticals, H&T Presspart Manufacturing Ltd., Findair Sp. z o. o., Vectura Group, Zeolr Technologies Pvt Ltd
Growth Drivers:
  • Increasing prevalence of respiratory diseases
  • Technological advancements
  • Increasing collaboration between pharma and digital health companies
Pitfalls & Challenges:
  • Lack of awareness regarding symptoms of asthma and COPD
  • Significant security risks and privacy issues

Request 15% Free Customization on this Report
 

Smart Inhalers Market, By Product

Dry Power Inhaler (DPI)- based smart inhalers segment is projected to witness more than 10.8% growth over the analysis timeframe. The DPI based smart inhalers contain add-on sensor developed by digital companies to work with dry powder inhaler manufactured by pharma companies. Recently, Teva introduced the digital dry powder inhaler, ProAir Digihaler with built-in sensors. The smart inhaler connects with the mobile application and provides inhaler use information to people with COPD and asthma. In the past years, various pharma companies collaborated with digital companies to develop smart inhalers. For instance, in August 2017, Propeller Health, a leading digital solution for respiratory medicine expanded its 2015 collaboration with GlaxoSmithKline to develop clip-on sensor and software platform for the ELLIPTA DPI Inhaler, a smart inhaler generally used for COPD treatment.
 

Metered Dose Inhaler (MDI)- based smart inhalers segment accounted for around 34% revenue share in 2018 in the smart inhalers market over the forecast period. The leading MDI manufacturers are focusing on collaborating with software and digital companies to serve the targeted population. Also, such collaborations and partnerships help manufacturers to launch their products more conveniently with enhanced distribution channel and thus drive the growth of the smart inhalers market.
 

Smart Inhalers Market, By Disease Indication

The asthma segment accounted for revenue of more than USD 50 million in 2018 and is projected to show significant growth during the forecast period. Asthma is considered as one of the most prevalent chronic inflammatory airway diseases. According to the Asthma and Allergy Foundation of America, more than 25 million Americans have asthma.  The growing prevalence of asthma will surge the growth of the segment.
 

The COPD segment is anticipated to hold a significant revenue share in 2018 and is projected to witness growth of 11.0% over the forthcoming years. The segment growth is attributable to the rising preference of COPD among the general population.
 

Germany Smart Inhalers Market Size, By Disease indication, 2018 (USD Million)
Germany Smart Inhalers Market Size, By Disease indication, 2018 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Smart Inhalers Market, By Distribution Channel

The hospital pharmacies segment is anticipated to hold a substantial market revenue share of around 38% in 2018 and is projected to witness a momentous growth during the forthcoming years. The hospital pharmacies are easily accessible to patients taking treatments from the hospital. Moreover, hospital pharmacies are very well connected with the smart inhaler distributors. The above-mentioned factors will escalate the smart inhaler availability in hospital pharmacies, thereby fostering segment growth.
 

Retail pharmacies are expected to hold a significant market share in the smart inhalers with a growth rate of 11.7% over the forthcoming years. Various companies have created smart inhaler devices but are not directly accessible to the patients. Recently, in April 2018, Adherium received FDA approval for over-the-counter sales of its smart inhaler sensor for AstraZeneca‘s Symbicort asthma inhaler. Furthermore, growing FDA approvals for over-the-counter sales of smart inhalers will accelerate the growth of segment revenue.
 

Smart inhalers Market, By Region

North America smart inhalers market was valued around USD 44 million revenue in 2018. This is majorly due to the rising per capita income that is driving people to spend more on health care. This factor is anticipated to positively influence the growth in treatment options for respiratory disorders. Also, technological advancements and affordability of smart inhalers among the target population are further anticipated to boost the North American market growth.  
 

Asia Pacific market is estimated to witness a growth pegged around 12.5% CAGR over the analysis timeline. The rising healthcare expenditure and an increasing number of product development is expected to drive the growth of the Asia Pacific market. India and China, along with other developing countries, are considered as the preferable destinations for investments and expenditure. The prime driving factors in the region are infrastructural developments, rapid industrialization, and economic growth. The growth in this region is paving way for considerable growth opportunities for smart inhaler manufacturers.
 

Asia Pacific Smart Inhalers Market Size, By Country, 2025 (USD Million)
Asia Pacific Smart Inhalers Market Size, By Country, 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Competitive Market Share

Some of the notable business players operating in smart inhalers market include AstraZeneca plc, GlaxoSmithKline, Aptar Pharma, Novartis, Boehringer Ingelheim, Teva Pharmaceuticals,  H&T Presspart Manufacturing Ltd., Findair Sp. z o. o., Vectura Group, and  Zeolr Technologies Pvt Ltd. Collaborations, partnerships, and agreements between digital and pharma companies play an important role in the market’s supply chain. The growing adoption of digitally improved inhalers across various end-use is driving the growth and innovation in the digital healthcare industry. The smart inhaler technology is becoming one of the most important areas of collaboration between digital health and pharma companies.
 

Recent industry developments:

  • In September 2017, Adherium received FDA approval for its new SmartTouch for Symbicort inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler. The increasing number of FDA approval for smart inhalers will benefit the digital monitoring of patients.
  •  
  • In February 2017, Propeller Health collaborated with Novartis to develop a custom add-on sensor for the Breezhaler inhaler. The collaboration will help in introducing smart inhalers to the market.
     

Smart Inhalers Industry Background

The development of the first commercial pressurized metered-dose inhalers (pMDIs) was marketed in 1956 as the first portable multidose delivery system. Since then, the pMDI has become the most commonly prescribed inhalation device to treat COPD and asthma. While, asthma and COPD are the very common respiratory disease, where the total medication costs are high. In 2004, GlaxoSmithKline launched the first pMDI with a built-in dose counter, Seretide Evohaler. The connected devices for asthma and COPD are becoming increasingly accessible, particularly smart inhalers that can accurately monitor, track, and prompt medication use. The smart inhaler was initially introduced in the U.S market to treat asthma and COPD. Smart inhalers are rapidly evolving as one of the most noticeable areas of pharmaceutical engagement in digital health. The increasing number of companies are embracing the use of this digital technology in order to enhance the respiratory diseases management and improve the effectiveness of prescribed medications.


Buy Now

Single User: $5,150 Access to only 1 person; cannot be shared; cannot be printed
Multi User: $7,150 Access for 2 to 5 users only within same department of one company
Enterprise User: $9,150 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Why Global Market Insights, Inc.?

Reliability & accuracy

  • GMI is unparalleled when to comes to the quality of research and information provided to clients. Our unique methodology is designed to ensure a minimum of 90% accuracy to give our clients excellent value on their investment.

Quality & trust


  • BBB Rating - Click to Verify

Customer service

  • Over 200 experts are available across various time-zones, ready to serve clients for their research needs. Our industry experts help clients to design reports customized to their needs.

Security & compliance

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X